Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Philip Robson


Senior Research Fellow (retired)

Therapeutic potential of cannabis-based medicines

Since the 1980s I have been intrigued by the medicinal properties of cannabis and its derivatives. In 1996 I was commissioned by the UK Department of Health to conduct a critical review of the relevant scientific literature and gave written and verbal evidence to the 1998 House of Lords Science and Technology Inquiry into the potential of cannabis medicines. The positive conclusions from this Inquiry alongside similar judgements from the US Institute of Medicine (1999) were an important stimulus to more rigorous pre-clinical and clinical investigation of this subject.

From 2000 - 2015 I took up the role of Medical Director of GW Pharmaceuticals, a company founded in 1998 in order to cultivate, extract and evaluate cannabinoid medicines, whilst retaining the post of Senior Research Fellow in this department. Early clinical research was carried out from a clinical base in Oxford but quickly became international in scope. Initially the focus was on serious neurological disorders such as multiple sclerosis and epilepsy, but lately I have been particularly interested in the therapeutic potential of cannabinoids in schizophrenia.

An earlier research interest was in the influence of self esteem in psychiatric disorders, which led to the development of the Robson Self Concept Scale.

Recent publications

More publications